o Specialty Pharmacy products o Diagnostic and genetic testing • Formulary management today is changing policies on benefit design and coverage for Specialty Pharmacy products • As testing demonstrates the value in averting future costs, health plans will adapt to provide better coverage REFERENCES • Plan benefit used for coverage of clinician-administered and oral biologic products are shown in Figure 6 o 70.9% expect no change and 29.1% expect to complete changes before December of 2018 o 78.6% expect no changes for the oral biologic benefit, 7.1% are currently changing; and expected to change before December 2017 (12.5%) and 2019 (1.8%) 
RESULTS
• A total of 61 persons completed the survey, some questions were not answered by all respondents • Many advisors reported multiple degrees (Figure 1) , and the most common degree was MD (59.2%) o Most (86%) of the advisors were involved in formulary decisions o Most advisors (83.6%) worked for a health plan-39.6% were local, 35.4% were national, and 25% were regional o Figure 2 shows the most commonly reported advisor titles The JeSTARx Group provides evidence-based research and support to the healthcare Industry.
The Pharmacy Group provides consulting services to the healthcare and pharmaceutical industry.
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